These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 32524494)
1. Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review. Robinson S; Boye KS; Mody R; Strizek AA; Konig M; Malik RE; Kennedy-Martin T Diabetes Ther; 2020 Jul; 11(7):1437-1466. PubMed ID: 32524494 [TBL] [Abstract][Full Text] [Related]
2. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain. Norrbacka K; Sicras-Mainar A; Lebrec J; Artime E; Díaz S; Tofé-Povedano S; Hernández I; Romera I Diabetes Ther; 2021 May; 12(5):1535-1551. PubMed ID: 33860927 [TBL] [Abstract][Full Text] [Related]
3. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States. Mody R; Huang Q; Yu M; Zhao R; Patel H; Grabner M; Landó LF Diabetes Obes Metab; 2019 Apr; 21(4):920-929. PubMed ID: 30520248 [TBL] [Abstract][Full Text] [Related]
4. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57). Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091 [TBL] [Abstract][Full Text] [Related]
5. Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study. Hoog M; Paczkowski R; Huang A; Halpern R; Buysman E; Stackland S; Zhang Y; Wangia-Dixon R Diabetes Ther; 2023 Nov; 14(11):1947-1958. PubMed ID: 37740872 [TBL] [Abstract][Full Text] [Related]
6. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK. Johansen P; Sandberg A; Capehorn M Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148 [TBL] [Abstract][Full Text] [Related]
7. Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results. Mody R; Yu M; Grabner M; Boye K; Teng CC; Kwan AYM Clin Ther; 2020 Nov; 42(11):2184-2195. PubMed ID: 33256915 [TBL] [Abstract][Full Text] [Related]
8. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis. Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629 [TBL] [Abstract][Full Text] [Related]
9. Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study. Mody R; Huang Q; Yu M; Patel H; Zhang X; Wang L; Grabner M BMJ Open Diabetes Res Care; 2019; 7(1):e000884. PubMed ID: 31875137 [TBL] [Abstract][Full Text] [Related]
10. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics. García-Pérez LE; Boye KS; Rosilio M; Jung H; Heitmann E; Norrbacka K; Federici MO; Gentilella R; Guerci B; Giorgino F; Aigner U; Sapin H Diabetes Ther; 2021 Jul; 12(7):1929-1946. PubMed ID: 34097244 [TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment. Mody R; Grabner M; Yu M; Turner R; Kwan AYM; York W; Fernández Landó L Curr Med Res Opin; 2018 Jun; 34(6):995-1003. PubMed ID: 29271258 [TBL] [Abstract][Full Text] [Related]
12. Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study. Hoog M; Maldonado JM; Wangia-Dixon R; Halpern R; Buysman E; Gremel GW; Huang A; Konig M Diabetes Ther; 2024 Apr; 15(4):855-867. PubMed ID: 38427164 [TBL] [Abstract][Full Text] [Related]
13. Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting. Uzoigwe C; Liang Y; Whitmire S; Paprocki Y Diabetes Ther; 2021 May; 12(5):1475-1489. PubMed ID: 33837922 [TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes. Berra CC; Resi V; Mirani M; Folini L; Rossi A; Solerte SB; Fiorina P Pharmacol Res; 2020 Sep; 159():104996. PubMed ID: 32574827 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Dulaglutide in the Real World and in Special Populations of Type 2 Diabetic Patients. Morieri ML; Frison V; Rigato M; D'Ambrosio M; Tadiotto F; Paccagnella A; Simioni N; Lapolla A; Avogaro A; Fadini GP J Clin Endocrinol Metab; 2020 Jul; 105(7):. PubMed ID: 32301492 [TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study. Tanaka K; Okada Y; Tokutsu A; Tanaka Y Sci Rep; 2022 Jan; 12(1):154. PubMed ID: 34997102 [TBL] [Abstract][Full Text] [Related]
17. Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study. Jain AB; Kanters S; Khurana R; Kissock J; Severin N; Stafford SG Diabetes Ther; 2021 Feb; 12(2):527-536. PubMed ID: 33367981 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757 [TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Hemmingsen B; Sonne DP; Metzendorf MI; Richter B Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]